Overview

* Kymera Q3 revenue missed analyst expectations

* Net loss for Q3 was $82.2 mln, reflecting increased R&D expenses

* Company remains well-capitalized with $979 mln cash, runway into 2H 2028

Outlook

* Kymera expects KT-621 Phase 1b trial data in December 2025

* Company plans to initiate KT-621 Phase 2b asthma trial in 1Q26

* Kymera anticipates KT-579 Phase 1 trial start in early 2026

Result Drivers

* STAT6 PROGRAM INVESTMENT - Increased R&D expenses driven by investment in STAT6 program and discovery initiatives

* KT-621 TRIAL PROGRESS - Completed enrollment and dosing in KT-621 Phase 1b trial for atopic dermatitis

* PHASE 2B TRIAL INITIATION - Initiated KT-621 Phase 2b trial in atopic dermatitis, with asthma trial planned for Q1 2026

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $2.76 $18.95

Revenue mln mln (20

Analysts

)

Q3 EPS -$0.94

Q3 Net -$82.17

Income mln

Q3 $95.28

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Kymera Therapeutics Inc ( KYMR ) is $70.00, about 14.7% above its November 3 closing price of $59.72

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)